# Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

> **NCT05643534** · PHASE3 · RECRUITING · sponsor: **Ardelyx** · enrollment: 180 (estimated)

## Conditions studied

- Irritable Bowel Syndrome With Constipation (IBS-C)

## Interventions

- **DRUG:** Tenapanor 50 MG
- **DRUG:** Tenapanor 25 mg bid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05643534
- **Lead sponsor:** Ardelyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-15
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05643534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05643534, "Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05643534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*